Literature DB >> 11707159

Current management of premenstrual syndrome and premenstrual dysphoric disorder.

L Born1, M Steiner.   

Abstract

About 5% of women of reproductive age experience affective or physical premenstrual symptoms that markedly influence work, social activities, or relationships. Prospective charting of symptoms for at least two menstrual cycles is required to facilitate an accurate diagnosis of premenstrual syndrome or premenstrual dysphoric disorder. The optimal treatment plan begins with lifestyle modifications, followed by pharmacotherapy. Evidence from numerous controlled trials has clearly demonstrated that low-dose serotonin reuptake inhibitors, using intermittent or continuous administration, have excellent efficacy with minimal side effects. Modification of the menstrual cycle should be considered only after all other treatment options have failed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11707159     DOI: 10.1007/s11920-001-0039-5

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   8.081


  71 in total

Review 1.  Complementary/alternative therapies for premenstrual syndrome: a systematic review of randomized controlled trials.

Authors:  C Stevinson; E Ernst
Journal:  Am J Obstet Gynecol       Date:  2001-07       Impact factor: 8.661

2.  Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression.

Authors:  K S Kendler; L M Karkowski; L A Corey; M C Neale
Journal:  Am J Psychiatry       Date:  1998-09       Impact factor: 18.112

3.  Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant.

Authors:  E W Freeman; K Rickels; F Arredondo; L C Kao; S E Pollack; S J Sondheimer
Journal:  J Clin Psychopharmacol       Date:  1999-02       Impact factor: 3.153

4.  Buspirone in treatment of premenstrual syndrome.

Authors:  K Rickels; E Freeman; S Sondheimer
Journal:  Lancet       Date:  1989-04-08       Impact factor: 79.321

5.  Fluoxetine in the treatment of premenstrual dysphoria.

Authors:  T P Su; P J Schmidt; M A Danaceau; M B Tobin; D L Rosenstein; D L Murphy; D R Rubinow
Journal:  Neuropsychopharmacology       Date:  1997-05       Impact factor: 7.853

6.  Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo.

Authors:  T B Pearlstein; U Halbreich; E D Batzar; C S Brown; J Endicott; E Frank; E W Freeman; W M Harrison; R F Haskett; A L Stout; K A Yonkers
Journal:  J Clin Psychiatry       Date:  2000-02       Impact factor: 4.384

7.  Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial.

Authors:  E W Freeman; K Rickels; S J Sondheimer; M Polansky
Journal:  Arch Gen Psychiatry       Date:  1999-10

8.  The neuroendocrine response to d-fenfluramine in women with premenstrual depression.

Authors:  J Bancroft; A Cook
Journal:  J Affect Disord       Date:  1995-12-24       Impact factor: 4.839

9.  Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?

Authors:  I Wikander; C Sundblad; B Andersch; I Dagnell; D Zylberstein; F Bengtsson; E Eriksson
Journal:  J Clin Psychopharmacol       Date:  1998-10       Impact factor: 3.153

10.  Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial.

Authors:  C S Brown; F W Ling; R N Andersen; R G Farmer; K L Arheart
Journal:  Obstet Gynecol       Date:  1994-11       Impact factor: 7.661

View more
  1 in total

Review 1.  Current update of hormonal and psychotropic drug treatment of premenstrual dysphoric disorder.

Authors:  Ellen W Freeman
Journal:  Curr Psychiatry Rep       Date:  2002-12       Impact factor: 5.285

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.